Californian health officials have asked for permission to use Novartis' unapproved meningitis B vaccine Bexsero to control an outbreak at a college.
GlaxoSmithKline's Advair is not your average off-patent blockbuster. It's difficult to copy, which has held off any major generic competition to date. Now, Novartis' generics unit Sandoz and its partner, Vectura, have won their first approval for a copy of the top-selling lung med--a reminder that the clock is ticking on Advair's turn at the top.
Japanese officials say they are preparing to prosecute Novartis for false advertising after two universities found falsified data in a disputed Diovan study, The Japan Times reports.
Should Novartis sell off its Roche stock, and soon? That's the question Bloomberg poses, now that Roche's voting shares are selling at a big discount to its nonvoting stock. With Novartis weighing all its operations for sale, spinoff, joint venture--what have you--the bet is that CEO Joe Jimenez will liquidate the Roche shares, too.
Novartis has been squeezing costs out of its eye product operations since buying Alcon for nearly $50 billion several years ago. Analysts at the time suggested there was at least $700 million in savings to be had, mostly through layoffs.
Novartis is recalling 42 batches of children's liquid cough and cold products in the U.K. because of a manufacturing issue reported by a contractor.
Workers at the plant in Mississauga, Ontario, got the news that layoffs will begin in May and operations will wind down by the end of next year.
Bexsero has always carried high expectations at Novartis. As the vaccine unit posted loss after loss in recent years, Novartis pitched the meningitis B vaccine to investors as the product that would usher in an era of consistent profitability. This is yet to happen, but the slow rollout of the vaccine continues.
Europe's antitrust crackdown in pharma marches on. Now, watchdogs are spanking Johnson & Johnson and Novartis for keeping a generic version of a powerful painkiller off the market.
Novartis Chairman Joerg Reinhardt and CEO Joe Jimenez were once in competition for the chief executive post. Jimenez won out; Reinhardt left to run Bayer Healthcare. Now, Reinhardt's back--but rather than wrest power away from Jimenez, he plans to give Jimenez more.